• Journal Article

Lapatinib plus capecitabine versus capecitabine alone for HER2+(ErbB2+) metastatic breast cancer: quality-of-life assessment

Citation

Zhou, X., Cella, D., Cameron, D., Amonkar, M. M., Segreti, A., Stein, S., ... Geyer, C. E. (2009). Lapatinib plus capecitabine versus capecitabine alone for HER2+(ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Research and Treatment, 117(3), 577-589.

Abstract